Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151160 | 0.80 | FAAH (0.37) | KMT2A | |
| SCHEMBL3246784 | 0.80 | — | — | |
| SCHEMBL23424122 | 0.77 | HMGCR (0.36) | KMT2AHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL17445678 | 0.77 | KMT2A (0.30) | KMT2A | |
| SCHEMBL116713 | 0.76 | — | — | |
| SCHEMBL7346515 | 0.76 | — | — | |
| SCHEMBL8011357 | 0.74 | — | — | |
| SCHEMBL18420497 | 0.73 | THRB (0.31) | — | |
| SCHEMBL7323593 | 0.73 | — | — | |
| SCHEMBL16208243 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9597327-B2 | Synthesis of (R)-N-methylnaltrexone | PROGENICS PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9475808-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | Progenics Pharmaceuticals., Inc. | 2015-10-15 | — | — | US | disclosed |
| US-9156771-B2 | Process for the preparation of enolate salts of 4-fluoro-2-hydroxymethylene-3 oxo-butyrates | LONZA LTD (CH) | 2015-10-13 | — | — | US | disclosed |
| US-9090592-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20130338394-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3 OXO-BUTYRATES | LONZA LTD. (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090268290-A1 | THERMOPLASTIC RESIN FILM AND METHOD FOR PRODUCING THEREOF | FUJIFILM CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090169810-A1 | THERMOPLASTIC FILM AND METHOD FOR PRODUCING THEREOF | FUJIFILM CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1951501-A1 | THERMOPLASTIC RESIN FILM AND METHOD FOR PRODUCING THEREOF | FUJIFILM Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070264448-A1 | Thermoplastic resin film and method of manufacturing the same | FUJIFILM CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| WO-2007060962-A1 | THERMOPLASTIC FILM AND METHOD FOR PRODUCING THEREOF | FUJIFILM CORPORATION (JP) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060964-A1 | THERMOPLASTIC RESIN FILM AND METHOD FOR PRODUCING THEREOF | FUJIFILM CORPORATION (JP) | 2007-05-31 | — | — | WO | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| US-4543413-A | Sulphonyl derivatives of N-phenyl pyridineamines | SHELL OIL COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137668-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE3B | KMT2A 2616/4885HMGCR 1517/4885CHRM1 21/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | KMT2A 1304/4885HMGCR 3833/4885CHRM1 1082/4885 |
| US-20130338394-A1 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3 OXO-BUTYRATES | ELOVL3, ELOVL1, EEF1B2 | KMT2A 310/4885HMGCR 965/4885CHRM1 276/4885 |
| US-20160002231-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE3A, PDE2A | KMT2A 2130/4885HMGCR 1955/4885CHRM1 55/4885 |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | KMT2A 2211/4885HMGCR 2023/4885CHRM1 60/4885 |
| US-20150290187-A1 | SYNTHESIS OF (R)-N-METHYLNALTREXONE | OPRM1, OPRL1, OPRK1 | KMT2A 526/4885HMGCR 756/4885CHRM1 209/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | KMT2A 1183/4885HMGCR 2417/4885CHRM1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.